Semathera
Westmount
About Semathera
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.6M
- Last round: Series Unknown (Mar 2018)
- Website: semathera.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Diabetes, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/semathera-190057 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.